Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions

Blood

Volumn 90, Issue 3, 1997, Pages 935-943

  Eischen, Christine M ^b   Kottke, Timothy J ^b   Martins, Luis M ^b   Basi, Guriqbal S ^b   Tung, Jay S ^b   Earnshaw, William C ^b   Leibson, Paul J ^b   Kaufmann, Scott H ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; METHOTREXATE; STAUROSPORINE; TOPOTECAN;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; GAMMA IRRADIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL LEUKEMIA;

EID: 0030806351     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.3.935.935_935_943     Document Type: Article

References (42)

1. Sen S, D'Incalci M: Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett 307:122, 1992
2. Dive C, Evans CA, Whetton AD: Induction of apoptosis -New targets for cancer chemotherapy. Semin Cancer Biol 3:417, 1992
3. Mesner P, Budihardjo I. Kaufmann SH: Chemotherapy-induced apoptosis. Adv Pharmacol 41:461, 1997
4. Kaufmann SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note. Cancer Res 49:5870, 1989
5. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40:2353, 1990
6. Bertrand R, Sarang M, Jenkin J, Kerrigan D, Pommier Y: Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified cmyc expression. Cancer Res 51:6280, 1991
7. Rubin E, Kharbanda S, Gunji H, Kufe D: Activation of the c-Jun protooncogene in human myeloid leukemia cells treated with etoposide. Mol Pharmacol 39:697, 1991
8. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC: Cleavage of poly(ADP-ribose)polymerase by a proteinase with properties like ICE. Nature 371:346, 1994
9. L inhibits ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 56:4743, 1996
10. Datta R, Banach D, Kojima H, Talanian RV, Alnemri ES, Wong WW. Kufe DW: Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood 88:1936, 1996
11. Martins LM, Kottke TJ, Mesner P, Basi GS, Sinha S, Frigon N, Jr., Tatar E, Tung JS, Bryant K, Takahashi A, Svingen PA, Madden BJ, McCormick DJ, Earnshaw WC, Kaufmann SH: Activation of multiple interleukin-1β converting enzyme homologues in cytosol and nuclei of HL-60 human leukemia cell lines during etoposide-induced apoptosis. J Biol Chem 272:7421, 1997
12. Alnemri ES, Livingston DJ, Nicholson DW, Salveson G, Thornberry NA, Wong WW, Yuan J: Human ICE/CED-3 protease nomenclature. Cell 87:171, 1996
13. Nicholson DW: ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis. Nature Biotech 14:297, 1996
14. Kaufmann SH: Proteolytic cleavage during chemotherapy-induced apoptosis. Mol Med Today 2:269, 1996
15. Takahashi A, Alnemri ES, Lazebnik YA, Fernandes-Alnemri T, Litwack G, Moir RD, Goldman RD, Poirier GG, Kaufmann SH, Earnshaw WC: Cleavage of lamin A by Mch2α but not CPP32: Multiple ICE-related proteases with distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci USA 93:8395, 1996
16. Orth K, Chinnaiyan AM, Garg M, Froelich CJ, Dixit VM: The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem 271:16443, 1996
17. Fraser A, Evan G: A license to kill. Cell 85:781, 1996
18. Eischen C, Leibson P: The Fas pathway in apoptosis. Adv Pharmacol 41:107, 1997
19. Nagata S: Apoptosis by death factor. Cell 88:355, 1997
20. Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B, Path M, Daniel PT, Knipping E, Westendorp MO: The role of APO-1-mediated apoptosis in the immune system. Immunol Rev 142:175, 1994
21. Nagata S, Golstein P: The Fas death factor. Science 267:1449, 1995
22. Fernandes-Alnemri T, Armstrong RC, Krebs J, Srinivasula SM, Wang L, Bullrich F, Fritz LC, Trapani JA, Tomaselli KJ, Litwack G, Alnemri ES: In vitro activation of CPP32 and Mch3 by Mch4, A Novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci USA 93:7464, 1996
23. Dubrez L, Savoy I, Hamman A, Solary E: Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. EMBO J 15:5504, 1996
24. Lotem J, Sachs L: Differential suppression by protease inhibitors and cytokines of apoptosis induced by wild-type p53 and cytotoxic agents. Proc Natl Acad Sci USA 93:12507, 1996
25. Moreno MB, Memon SA, Zacharchuk CM: Apoptosis signaling pathways in normal T cells. J Immunol 157:3845, 1996
26. Ucker DS: Death and dying in the immune system. Adv Pharmacol 41:179, 1997
27. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J: Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53:4251, 1993
28. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151, 1993
29. Chinnaiyan AM, Orth K, O'Rouke K, Duan H, Poirier GG, Dixit VM: Molecular ordering of the cell death pathway. J Biol Chem 271:4573, 1996
30. Wang X, Zelenski NG, Yang J, Sakai J, Brown MS, Goldstein JL: Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis. EMBO J 15:1012, 1996
31. Friesen C, Herr I, Krammer PH, Debatin K-M: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 2:574, 1996
32. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J-C, Tschopp J: Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274:1363, 1996
33. Müller M, Strand S, Hug H, Heinemann E-M, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR: Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1-Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99:403, 1997
34. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CR, Knapp DJ, Green DR, Kratzke RA: Human lung carcinomas express Fas ligand. Cancer Res 57:1007, 1997
35. Eischen CM, Dick CJ, Leibson PJ: Tyrosine kinase activation provides an early and requisite signal for Fas-induced apoptosis. J Immunol 153:1947, 1994
36. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem 150:76, 1985
37. Kaufmann SH, McLaughlin SJ, Kastan M, Liu LF, Karp JE, Burke PJ: Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 51:3534, 1991
38. Eischen CM, Williams BL, Zhang W, Samelson WE, Lynch DH, Abraham RT, Leibson PJ: Zap70 tyrosine kinase is required for the up-regulation of Fas ligand in activation-induced T cell apoptosis. J Immunol 1997 (in press)
39. Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell 85:803, 1996
40. Lazebnik YA, Takahaski A, Moir R, Goldman R, Poirier GG, Kaufmann SH, Earnshaw WC: Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Proc Natl Acad Sci USA 92:9042, 1995
41. Yonehara S, Nishimura Y, Kishil S, Yonehara M, Takazawa K, Tamatani T, Ishii A: Involvement of apoptosis antigen Fas in cloncal deletion of human thymocytes. Int Immunol 6:1849, 1994
42. Dhein JH, Walczak H, Baumler C, Debatin KM, Krammer PH: Autocrine T-cell suicide mediated by APO-1/(Fas/DC95). Nature 373:438, 1995